Comparative study of inhibition at multiple stages of amyloid-β self-assembly provides mechanistic insight

Timothy J. Davis, Deborah D. Soto-Ortega, Joseph A. Kotarek, Francisco J. Gonzalez-Velasquez, Krishnamoothy Sivakumar, Laying Wu, Qian Wang, Melissa A. Moss

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The "amyloid cascade hypothesis," linking self-assembly of the amyloid-β protein (Aβ) to the pathogenesis of Alzheimer's disease, has led to the emergence of inhibition of Aβ self-assembly as a prime therapeutic strategy for this currently unpreventable and devastating disease. The complexity of Aβ self-assembly, which involves multiple reaction intermediates related by nonlinear and interconnected nucleation and growth mechanisms, provides multiple points for inhibitor intervention. Although a number of small-molecule inhibitors of Aβ self-assembly have been identified, little insight has been garnered concerning the point at which these inhibitors intervene within the Aβ assembly process. In the current study, a julolidine derivative is identified as an inhibitor of Aβ self-assembly. To gain insight into the mechanistic action of this inhibitor, the inhibition of fibril formation from monomeric protein is assessed quantitatively and compared with the inhibition of two distinct mechanisms of growth for soluble Aβ aggregation intermediates. This compound is observed to significantly inhibit soluble aggregate growth by lateral association while having little effect on soluble aggregate elongation via monomer addition. In addition, inhibition of soluble Aβ aggregate association exhibits an IC50 with a somewhat lower stoichiometric ratio than the IC50 determined for inhibition of fibril formation from monomeric Aβ. This quantitative comparison of inhibition within multiple Aβ self-assembly assays suggests that this compound binds the lateral surface of on-pathway intermediates exhibiting a range of sizes to prevent their association with other aggregates, which is required for further assembly into mature fibrils.

Original languageEnglish
Pages (from-to)405-413
Number of pages9
JournalMolecular Pharmacology
Volume76
Issue number2
DOIs
StatePublished - 1 Aug 2009

Fingerprint

Amyloid
Inhibitory Concentration 50
Growth
Serum Amyloid A Protein
Inhibition (Psychology)
Alzheimer Disease
Proteins

Cite this

Davis, T. J., Soto-Ortega, D. D., Kotarek, J. A., Gonzalez-Velasquez, F. J., Sivakumar, K., Wu, L., ... Moss, M. A. (2009). Comparative study of inhibition at multiple stages of amyloid-β self-assembly provides mechanistic insight. Molecular Pharmacology, 76(2), 405-413. https://doi.org/10.1124/mol.109.055301
Davis, Timothy J. ; Soto-Ortega, Deborah D. ; Kotarek, Joseph A. ; Gonzalez-Velasquez, Francisco J. ; Sivakumar, Krishnamoothy ; Wu, Laying ; Wang, Qian ; Moss, Melissa A. / Comparative study of inhibition at multiple stages of amyloid-β self-assembly provides mechanistic insight. In: Molecular Pharmacology. 2009 ; Vol. 76, No. 2. pp. 405-413.
@article{306b6a0a8d354d7699e53e304dcacee9,
title = "Comparative study of inhibition at multiple stages of amyloid-β self-assembly provides mechanistic insight",
abstract = "The {"}amyloid cascade hypothesis,{"} linking self-assembly of the amyloid-β protein (Aβ) to the pathogenesis of Alzheimer's disease, has led to the emergence of inhibition of Aβ self-assembly as a prime therapeutic strategy for this currently unpreventable and devastating disease. The complexity of Aβ self-assembly, which involves multiple reaction intermediates related by nonlinear and interconnected nucleation and growth mechanisms, provides multiple points for inhibitor intervention. Although a number of small-molecule inhibitors of Aβ self-assembly have been identified, little insight has been garnered concerning the point at which these inhibitors intervene within the Aβ assembly process. In the current study, a julolidine derivative is identified as an inhibitor of Aβ self-assembly. To gain insight into the mechanistic action of this inhibitor, the inhibition of fibril formation from monomeric protein is assessed quantitatively and compared with the inhibition of two distinct mechanisms of growth for soluble Aβ aggregation intermediates. This compound is observed to significantly inhibit soluble aggregate growth by lateral association while having little effect on soluble aggregate elongation via monomer addition. In addition, inhibition of soluble Aβ aggregate association exhibits an IC50 with a somewhat lower stoichiometric ratio than the IC50 determined for inhibition of fibril formation from monomeric Aβ. This quantitative comparison of inhibition within multiple Aβ self-assembly assays suggests that this compound binds the lateral surface of on-pathway intermediates exhibiting a range of sizes to prevent their association with other aggregates, which is required for further assembly into mature fibrils.",
author = "Davis, {Timothy J.} and Soto-Ortega, {Deborah D.} and Kotarek, {Joseph A.} and Gonzalez-Velasquez, {Francisco J.} and Krishnamoothy Sivakumar and Laying Wu and Qian Wang and Moss, {Melissa A.}",
year = "2009",
month = "8",
day = "1",
doi = "10.1124/mol.109.055301",
language = "English",
volume = "76",
pages = "405--413",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

Davis, TJ, Soto-Ortega, DD, Kotarek, JA, Gonzalez-Velasquez, FJ, Sivakumar, K, Wu, L, Wang, Q & Moss, MA 2009, 'Comparative study of inhibition at multiple stages of amyloid-β self-assembly provides mechanistic insight', Molecular Pharmacology, vol. 76, no. 2, pp. 405-413. https://doi.org/10.1124/mol.109.055301

Comparative study of inhibition at multiple stages of amyloid-β self-assembly provides mechanistic insight. / Davis, Timothy J.; Soto-Ortega, Deborah D.; Kotarek, Joseph A.; Gonzalez-Velasquez, Francisco J.; Sivakumar, Krishnamoothy; Wu, Laying; Wang, Qian; Moss, Melissa A.

In: Molecular Pharmacology, Vol. 76, No. 2, 01.08.2009, p. 405-413.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparative study of inhibition at multiple stages of amyloid-β self-assembly provides mechanistic insight

AU - Davis, Timothy J.

AU - Soto-Ortega, Deborah D.

AU - Kotarek, Joseph A.

AU - Gonzalez-Velasquez, Francisco J.

AU - Sivakumar, Krishnamoothy

AU - Wu, Laying

AU - Wang, Qian

AU - Moss, Melissa A.

PY - 2009/8/1

Y1 - 2009/8/1

N2 - The "amyloid cascade hypothesis," linking self-assembly of the amyloid-β protein (Aβ) to the pathogenesis of Alzheimer's disease, has led to the emergence of inhibition of Aβ self-assembly as a prime therapeutic strategy for this currently unpreventable and devastating disease. The complexity of Aβ self-assembly, which involves multiple reaction intermediates related by nonlinear and interconnected nucleation and growth mechanisms, provides multiple points for inhibitor intervention. Although a number of small-molecule inhibitors of Aβ self-assembly have been identified, little insight has been garnered concerning the point at which these inhibitors intervene within the Aβ assembly process. In the current study, a julolidine derivative is identified as an inhibitor of Aβ self-assembly. To gain insight into the mechanistic action of this inhibitor, the inhibition of fibril formation from monomeric protein is assessed quantitatively and compared with the inhibition of two distinct mechanisms of growth for soluble Aβ aggregation intermediates. This compound is observed to significantly inhibit soluble aggregate growth by lateral association while having little effect on soluble aggregate elongation via monomer addition. In addition, inhibition of soluble Aβ aggregate association exhibits an IC50 with a somewhat lower stoichiometric ratio than the IC50 determined for inhibition of fibril formation from monomeric Aβ. This quantitative comparison of inhibition within multiple Aβ self-assembly assays suggests that this compound binds the lateral surface of on-pathway intermediates exhibiting a range of sizes to prevent their association with other aggregates, which is required for further assembly into mature fibrils.

AB - The "amyloid cascade hypothesis," linking self-assembly of the amyloid-β protein (Aβ) to the pathogenesis of Alzheimer's disease, has led to the emergence of inhibition of Aβ self-assembly as a prime therapeutic strategy for this currently unpreventable and devastating disease. The complexity of Aβ self-assembly, which involves multiple reaction intermediates related by nonlinear and interconnected nucleation and growth mechanisms, provides multiple points for inhibitor intervention. Although a number of small-molecule inhibitors of Aβ self-assembly have been identified, little insight has been garnered concerning the point at which these inhibitors intervene within the Aβ assembly process. In the current study, a julolidine derivative is identified as an inhibitor of Aβ self-assembly. To gain insight into the mechanistic action of this inhibitor, the inhibition of fibril formation from monomeric protein is assessed quantitatively and compared with the inhibition of two distinct mechanisms of growth for soluble Aβ aggregation intermediates. This compound is observed to significantly inhibit soluble aggregate growth by lateral association while having little effect on soluble aggregate elongation via monomer addition. In addition, inhibition of soluble Aβ aggregate association exhibits an IC50 with a somewhat lower stoichiometric ratio than the IC50 determined for inhibition of fibril formation from monomeric Aβ. This quantitative comparison of inhibition within multiple Aβ self-assembly assays suggests that this compound binds the lateral surface of on-pathway intermediates exhibiting a range of sizes to prevent their association with other aggregates, which is required for further assembly into mature fibrils.

UR - http://www.scopus.com/inward/record.url?scp=67650844215&partnerID=8YFLogxK

U2 - 10.1124/mol.109.055301

DO - 10.1124/mol.109.055301

M3 - Article

C2 - 19483107

AN - SCOPUS:67650844215

VL - 76

SP - 405

EP - 413

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 2

ER -